ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer

Biochemistry, Genetics and Molecular Biology

• Actin 50%
• Binding Protein 50%
• Carcinogenesis 50%
• CDC42 50%
• Cell Function 50%
• Cell Junction 50%
• Cell Polarity 100%
• Chromosomal Translocation 50%
• Cofilin 50%
• Genomics 50%
• Mesenchymal-Epithelial Transition 100%
• Phospholipid 50%
• Promoter Region 50%
• Refined Hydrothermolytic Oxidation Acid 50%
• RNA 50%
• Small Interfering RNA 50%
• TMPRSS2 50%
• Transcription Initiation Site 50%

Keyphrases

• Actin Filaments 8%
• Annexin A2 (ANXA2) 100%
• Ca2+ Dependence 8%
• Cdc42 8%
• Cell Behavior 8%
• Cell Formation 8%
• Cell Polarity 8%
• Cell-cell Junctions 8%
• Chromosomal Translocation 8%
• Clinical Specimens 8%
• Cofilin 8%
• Differentiated Cells 8%
• Epithelial Phenotype 8%
• Epithelial Polarity 8%
• Epithelial-mesenchymal Transition 16%
• Genomic Analysis 8%
• Immunohistochemistry 8%
• Knockdown 8%
• Mechanistic Studies 8%
• MRNA Level 8%
• Oncoprotein 100%
• Overexpression 16%
• Phospholipid-binding Protein 8%
• Poor Differentiation 16%
• Primary Prostate Cancer 8%
• Prostate Cancer 100%
• Prostate Cells 8%
• Prostate Epithelial Cells 8%
• Prostate Epithelium 8%
• Prostate Tumorigenesis 8%
• Prostate-specific 8%
• Protein Level 8%
• Reciprocal Relationship 8%
• Small Interfering RNA (siRNA) 8%
• Therapeutic Targeting 8%
• TMPRSS2-ERG Fusion 8%
• Transcription Start Site 8%
• Transcriptional Repression 16%
• Tumor 16%
• Well-differentiated 8%